3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
2
Unknown
1
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Small Cell Lung Carcinoma
2
Neoplasms
2
Head and Neck Neoplasms
2
Gastrointestinal Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Merkel Cell
2
Breast Neoplasms
2
Urinary Bladder Neoplasms
1
Turcot syndrome
1
Stomach Neoplasms
1
Sarcoma
1
Penile Neoplasms
1
PD-L1 Positive Mutation Tumor
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasm Metastasis
1
Mesothelioma, Malignant
1
Melanoma
1
Lymphoma, Extranodal NK-T-Cell
1
Leukemia, Myeloid, Chronic-Phase
1
Hodgkin Disease
1
Hemangiosarcoma
1
Glioblastoma
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Hepatocellular
1
Carcinoma
1
Interventions
Doxorubicin
19
Radiotherapy
10
Ifosfamide
10
apatinib
9
anlotinib
8
Cyclophosphamide
8
camrelizumab
7
Vincristine
5
Dactinomycin
5
toripalimab
3
Trabectedin
3
Radiation Dose Hypofractionation
3
Ipilimumab
3
Gemcitabine
3
Etoposide
3
Docetaxel
3
selinexor
2
ribociclib
2
envafolimab
2
brostallicin
2
Topotecan
2
Thalidomide
2
Temozolomide
2
Sorafenib
2
Oncolytic Virotherapy
2
Nivolumab
2
Neoadjuvant Therapy
2
Melphalan
2
Magnetic Resonance Spectroscopy
2
Irinotecan
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Sarcoma
×
avelumab
×
Clear all
NCT02630368
2022-02-02
METROmaJX
Institut Bergonié
Phase 1/2
Unknown
197 enrolled